Amgen Declares Third Quarter 2025 Dividend of $2.38 Per Share
Amgen, a leading biotechnology company based in Thousand Oaks, California, has recently declared a dividend of $2.38 per share for the third quarter of 2025. The announcement was made on August 1, 2025, as part of the company's ongoing commitment to returning value to its shareholders. The dividend is set to be distributed on September 12, 2025, to all shareholders who are on record as of the close of business on August 22, 2025. This announcement reflects Amgen's strong financial performance amid a competitive industry environment.
Founded over 40 years ago, Amgen has played a crucial role in establishing and advancing the biotechnology industry. It focuses on developing innovative therapies for some of the most challenging diseases, including cancer, heart disease, osteoporosis, and rare diseases, utilizing both technology and genetic research to drive its innovations. The company is renowned for its extensive and ambitious pipeline that continually builds upon its existing portfolio of medications aimed at improving patient outcomes.
In recent years, Amgen's achievements have been acknowledged by several prestigious publications. In 2024, Fast Company listed it among the 'World's Most Innovative Companies'. Additionally, Forbes recognized Amgen as one of 'America's Best Large Employers,' highlighting its commitment to fostering a positive work environment.
Amgen is included in the Dow Jones Industrial Average®, a testament to its prominence in the market, as well as the Nasdaq-100 Index®, which represents the largest non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
The announcement of the quarterly dividend is part of Amgen’s overall strategy to maintain strong relations with its investors while transparently indicating its financial health and operational success. This decision is particularly significant as dividends can signal to the market that a company is confident about its future earnings potential.
As a proactive innovator, Amgen consistently invests in research and development, focusing on addressing unmet medical needs and enhancing the lives of patients globally through biotechnology. The company’s dedication to advancing healthcare solutions continues to drive its success, which is reflected in its decision to distribute dividends to shareholders.
Despite the uncertainties surrounding the global economy and the biotech sector's inherent challenges, Amgen's leadership remains optimistic about its growth trajectory and ability to navigate market conditions effectively. With each dividend declared, Amgen reiterates its commitment to delivering value to its stakeholders, reinforcing its position as a leader in the biotechnology industry.
Shareholders are encouraged to stay informed about Amgen's future announcements and other financial updates by visiting the official Amgen website or following the company on various social media platforms, including X, LinkedIn, Instagram, YouTube, and Threads.
Overall, as Amgen prepares to distribute its quarterly dividend, it does so with a robust foundation of innovative practices and a commitment to healthcare advancement, placing itself at the forefront of the biotechnology landscape. With a clear vision for the future, Amgen continues to strive for excellence in its field, proving to be a reliable companion for its investors and partners alike.
Founded over 40 years ago, Amgen has played a crucial role in establishing and advancing the biotechnology industry. It focuses on developing innovative therapies for some of the most challenging diseases, including cancer, heart disease, osteoporosis, and rare diseases, utilizing both technology and genetic research to drive its innovations. The company is renowned for its extensive and ambitious pipeline that continually builds upon its existing portfolio of medications aimed at improving patient outcomes.
In recent years, Amgen's achievements have been acknowledged by several prestigious publications. In 2024, Fast Company listed it among the 'World's Most Innovative Companies'. Additionally, Forbes recognized Amgen as one of 'America's Best Large Employers,' highlighting its commitment to fostering a positive work environment.
Amgen is included in the Dow Jones Industrial Average®, a testament to its prominence in the market, as well as the Nasdaq-100 Index®, which represents the largest non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
The announcement of the quarterly dividend is part of Amgen’s overall strategy to maintain strong relations with its investors while transparently indicating its financial health and operational success. This decision is particularly significant as dividends can signal to the market that a company is confident about its future earnings potential.
As a proactive innovator, Amgen consistently invests in research and development, focusing on addressing unmet medical needs and enhancing the lives of patients globally through biotechnology. The company’s dedication to advancing healthcare solutions continues to drive its success, which is reflected in its decision to distribute dividends to shareholders.
Despite the uncertainties surrounding the global economy and the biotech sector's inherent challenges, Amgen's leadership remains optimistic about its growth trajectory and ability to navigate market conditions effectively. With each dividend declared, Amgen reiterates its commitment to delivering value to its stakeholders, reinforcing its position as a leader in the biotechnology industry.
Shareholders are encouraged to stay informed about Amgen's future announcements and other financial updates by visiting the official Amgen website or following the company on various social media platforms, including X, LinkedIn, Instagram, YouTube, and Threads.
Overall, as Amgen prepares to distribute its quarterly dividend, it does so with a robust foundation of innovative practices and a commitment to healthcare advancement, placing itself at the forefront of the biotechnology landscape. With a clear vision for the future, Amgen continues to strive for excellence in its field, proving to be a reliable companion for its investors and partners alike.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.